NCT06361316View on ClinicalTrials.gov

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

NARecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

March 25, 2025

Study Completion Date

July 31, 2028

Conditions
Pancreatic CancerAdjuvant Therapy
Interventions
DRUG

Irinotecan liposome injection

Postoperative adjuvant therapy

Trial Locations (1)

025

RECRUITING

FirstNanjingMU, Nanjing

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Kuirong Jiang

OTHER

NCT06361316 - Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer | Biotech Hunter | Biotech Hunter